SAA2 Inhibitors
Chemical inhibitors of SAA2 function through various molecular mechanisms to disrupt the protein's activity. Chloroquine acts by increasing the pH within endosomes, which can inhibit the acidification process essential for the endosomal-lysosomal trafficking of SAA2. As a result, the processing or secretion of SAA2 may be hindered. Another inhibitor, Cyclosporin A, targets the immune system's calcineurin pathway. By inhibiting calcineurin, Cyclosporin A can interfere with the signaling pathways that regulate SAA2's activity in the immune response. GW4869's mode of action is through the inhibition of neutral sphingomyelinase, an enzyme involved in ceramide production. Ceramide is a lipid molecule that participates in inflammatory signaling, which suggests that GW4869 can inhibit SAA2's function by disrupting ceramide-mediated pathways.
PD98059, a selective inhibitor of MAPK/ERK kinase, and BAY 11-7085, which inhibits NF-kB activation, both act on signaling pathways that are important for the activity of SAA2 during the acute phase response. By blocking these pathways, these inhibitors can suppress SAA2's function in inflammation. SP600125 and SB203580 target different kinases involved in stress and inflammatory responses, namely the c-Jun N-terminal kinase and p38 MAP kinase, respectively. By inhibiting these kinases, SP600125 and SB203580 can disrupt the signaling required for SAA2's involvement in these responses. Y-27632, which inhibits Rho-associated protein kinase, and Manumycin A, a selective inhibitor of Ras farnesyltransferase, both affect signaling pathways that may be crucial for SAA2's functional effects in inflammation. Inhibition by Y-27632 can result from altered actin cytoskeleton dynamics, while Manumycin A can interfere with Ras signaling. Lastly, Exo1 and JSH-23 affect the release and activity of SAA2 by inhibiting exosome secretion and NF-kB nuclear translocation, respectively, which are processes that can modulate the function of SAA2 in the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine, an antimalarial drug, can inhibit endosomal acidification. SAA2 is known to be involved in the acute phase response and may require endosomal-lysosomal trafficking for its processing or secretion. By raising endosomal pH, Chloroquine could inhibit the proper functioning of SAA2. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A, an immunosuppressant, inhibits the activity of calcineurin. Since SAA2 is involved in the immune response, calcineurin inhibition can disrupt the signaling pathways that lead to the functional activity of SAA2, thus inhibiting its function. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is an inhibitor of neutral sphingomyelinase (nSMase), which plays a role in ceramide generation. As ceramide can be involved in inflammatory signaling pathways to which SAA2 contributes, GW4869 can inhibit SAA2 function by disrupting ceramide-mediated signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MAPK/ERK kinase. By blocking ERK pathway activation, PD98059 can inhibit the signaling required for SAA2 function during the acute phase response. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $122.00 $516.00 | 55 | |
BAY 11-7085 is an inhibitor of NF-kB activation. SAA2 is a protein whose expression is regulated by NF-kB during inflammation. By inhibiting NF-kB, BAY 11-7085 can inhibit the function of SAA2 by preventing its action in inflammatory signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is involved in stress and inflammatory responses, which can regulate the function of SAA2. SP600125 can inhibit SAA2 by blocking JNK signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. SAA2 is involved in inflammatory responses and could be regulated by p38 MAP kinase signaling. SB203580 can inhibit SAA2 by blocking p38 MAPK-mediated signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). As SAA2 is implicated in various cellular processes that could be modulated by ROCK through actin cytoskeleton rearrangement, Y-27632 can inhibit SAA2 through disruption of ROCK signaling. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $215.00 $622.00 | 5 | |
Manumycin A is a selective inhibitor of Ras farnesyltransferase. SAA2 activity may require Ras-mediated signaling for its functional effects in inflammation. Manumycin A can inhibit SAA2 by disrupting Ras signaling pathways. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $82.00 $291.00 | 4 | |
Exo1 is a selective inhibitor of exosome release. SAA2 might be secreted or have its function modulated via exosomal pathways. Exo1 can inhibit SAA2 function by preventing its release in exosomes. | ||||||